Patents Assigned to Taiho Pharmaceuticals Co., Ltd.
  • Salt of fused pyrimidine compound and crystal thereof
    Patent number: 10280174
    Abstract: Provided is a salt having a high selectivity to BTK and is useful as a drug ingredient for a pharmaceutical product. It has been found that fumarate of Compound A is free of a characteristic of channel hydrate and is stable and excellent in absorptive property, compared to Compound A or other salts thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: May 7, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Hiromi Oshiumi
  • Crystal of uracil compound
    Patent number: 10259792
    Abstract: The present invention provides a crystal that has preferable oral absorption and can be obtained with particularly preferable reproducibility. Provided is a crystal of (R)—N-(1-(3-(cyclopentyloxy)phenyl)ethyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 16, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Masayoshi Fukuoka
  • FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
    Publication number: 20190092776
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 28, 2019
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Isao MIYAZAKI, Tadashi SHIMAMURA, Masanori KATO, Hidenori FUJITA
  • Fused pyrimidine compound or salt thereof
    Patent number: 10233189
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: March 19, 2019
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita
  • ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR, AND ANTITUMOR EFFECT POTENTIATOR
    Publication number: 20190046639
    Abstract: Provided is a novel cancer treatment method with less side effects, showing remarkably excellent antitumor effect. An antitumor agent is used for administering a DNA function inhibitor and an immunomodulator in combination.
    Type: Application
    Filed: January 6, 2017
    Publication date: February 14, 2019
    Applicant: TAIHO PHARMACEUTICAL CO., LTD
    Inventor: Norihiko SUZUKI
  • THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER
    Publication number: 20190015417
    Abstract: The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.
    Type: Application
    Filed: October 2, 2018
    Publication date: January 17, 2019
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Hiroshi SOOTOME
  • Fused pyrimidine compound or salt thereof
    Patent number: 10179788
    Abstract: The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malignant tumors) that can be prevented or treated by RET inhibitory activity. The RET inhibitor comprises, as an active ingredient, a compound represented by Formula (I) below or a salts thereof: wherein A, R1 to R3, X, and n are as defined in the specification.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: January 15, 2019
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita
  • Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof
    Patent number: 10174040
    Abstract: A pyrrolopyrimidine compound or a salt thereof and compositions, NAE inhibitors and anti-tumor agents containing the pyrrolopyrimidine compound or a salt thereof.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: January 8, 2019
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Takashi Mizutani, Chihoko Yoshimura, Hitomi Kondo, Makoto Kitade, Shuichi Ohkubo
  • NOVEL PIPERIDINE COMPOUND OR SALT THEREOF
    Publication number: 20180369224
    Abstract: A piperidine compound represented by a general formula (I) or a salt thereof: wherein, R1 represents a carboxyl group, —C(?O)NR5R6, or an oxadiazolyl group optionally having a C1-C6 alkyl group or a trifluoromethyl group as a substituent; R2 represents a halogen atom or a C1-C6 alkoxy group; R3 represents a phenyl group optionally having 1 to 3 same or different group(s) selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, and a trifluoromethyl group as a substituent; R4 represents a hydrogen atom or a C1-C6 alkyl group; and R5 and R6 are the same or different and each represent a hydrogen atom, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, or R5 and R6 optionally form a 3 to 6-membered nitrogen-containing saturated heterocyclic group together with a nitrogen atom to which R5 and R6 are bound, are provided.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 27, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya SUGIMOTO, Hidekazu TAKAHASHI, Morihiro MITSUYA, Norio MASUKO, Hiroshi SOOTOME
  • Fused pyrimidine compound or salt thereof
    Patent number: 10155768
    Abstract: The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R2, and X are as defined in the specification; or a salt thereof.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: December 18, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Isao Miyazaki, Tadashi Shimamura, Masanori Kato, Hidenori Fujita, Satoru Iguchi
  • NOVEL BIPHENYL COMPOUND OR SALT THEREOF
    Publication number: 20180354960
    Abstract: A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.
    Type: Application
    Filed: November 25, 2016
    Publication date: December 13, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Satoshi YAMASHITA, Takahiro OGAWA, Hideya KOMATANI
  • Mesylic acid salt of acylthiourea compound, crystal of the same, and process for producing these
    Patent number: 10143688
    Abstract: An object of the present invention is to provide a salt compound of 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide, which is useful as an antitumor agent, and crystal of the salt. The salt and the crystal are excellent in terms of solubility, stability, and peroral absorbability and can be mass-produced. The present invention relates to: a mesylic acid salt of 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide; and the mesylic acid salt including a crystal which gives an X-ray powder diffraction spectrum having characteristic peaks at specific diffraction angles.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 4, 2018
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Ayako Sato
  • METHOD FOR TREATING CANCER PATIENTS WITH SEVERE RENAL IMPAIRMENT
    Publication number: 20180338976
    Abstract: A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 50 mg/m2/day as FTD-equivalent, into two to four times a day, and orally administering it to the patient.
    Type: Application
    Filed: August 3, 2018
    Publication date: November 29, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Kenichiro YOSHIDA
  • Stable crystal form of tipiracil hydrochloride and crystallization method for the same
    Patent number: 10138223
    Abstract: An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4 (1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4 (1H,3H)-pyrimidinedione hydrochloride exhibiting characteristic peaks at angles of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2?±0.1°) in powder X-ray diffraction.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: November 27, 2018
    Assignee: TAIHO PHARMACEUTICALS CO., LTD.
    Inventors: Hideki Kazuno, Tomonobu Mutsumi
  • Peptide compositions having 4 linked CTL epitopes and uses thereof
    Patent number: 10137183
    Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 4 linked CTL epitopes is obtained by linking 4 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 27, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Satoshi Fukaya, Toshihiro Osada, Hiroshi Wada
  • Therapeutic agent for FGFR inhibitor-resistant cancer
    Patent number: 10124003
    Abstract: The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 13, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventor: Hiroshi Sootome
  • FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
    Publication number: 20180312505
    Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).
    Type: Application
    Filed: November 25, 2016
    Publication date: November 1, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhisa MINAMIGUCHI, Shigeo OKAJIMA, Takahiro ASAI, Masanori ASAI, Yoshio OGINO
  • Resistant mutant 90 kDa heat shock protein
    Patent number: 10100095
    Abstract: An object to be solved by the present invention is to identify patients resistant to known HSP90 inhibitors, and to provide a novel therapeutic agent for treating the patients who have become resistant to known HSP90 inhibitors. As a means for solving the above problems, the present invention provides identification of the patients based on a protein, which is an HSP90 family protein having a mutation in the site corresponding to F138 of HSP90? class A consisting of the amino acid sequence of SEQ ID NO: 1, and use of a substance that inhibits the protein as an active ingredient of a therapeutic agent.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: October 16, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Chihoko Yoshimura, Yasuo Kodama, Shuichi Ohkubo
  • THERAPEUTIC AGENT FOR FIBROSIS
    Publication number: 20180289690
    Abstract: Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.
    Type: Application
    Filed: June 24, 2016
    Publication date: October 11, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Akio FUJIOKA
  • STABLE CRYSTAL FORM OF TIPIRACIL HYDROCHLORIDE AND CRYSTALLIZATION METHOD FOR THE SAME
    Publication number: 20180291005
    Abstract: Crystal Form I of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting powder X-ray peaks at two or more angles selected from the group consisting of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2?±0.2°).
    Type: Application
    Filed: May 2, 2018
    Publication date: October 11, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hideki KAZUNO, Tomonobu MUTSUMI